Article
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.
Blood - 26 Oct 2017
Eskelund Christian W, Dahl Christina, Hansen Jakob W, Westman Maj, Kolstad Arne, Pedersen Lone B, Montano-Almendras Carmen P, Husby Simon, Freiburghaus Catja, Ek Sara, Pedersen Anja, Niemann Carsten, Räty Riikka, Brown Peter, Geisler Christian H, Andersen Mette K, Guldberg Per, Jerkeman Mats, Grønbæk Kirsten
Abstract excerpt
Despite recent advances in lymphoma treatment, mantle cell lymphoma (MCL) remains incurable, and we are still unable to identify patients who will not benefit from the current standard of care. Here, we explore the prognostic value of recurrent genetic aberrations in diagnostic bone marrow (BM) specimens from 183 younger patients with MCL from the Nordic MCL2 and MCL3 trials, which represent current...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.